Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.

Autor: Yanai H; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Salomon N; Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel., Lahat A; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel., Ungar B; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel., Eliakim R; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel., Kriger-Sharabi O; Department of Gastroenterology, Assuta Medical Center, Ashdod, Israel., Reiss-Mintz H; Department of Gastroenterology, Mayanei HaYeshua Medical Center, Bnei Brak, Israel., Koslowsky B; Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Shitrit AB; Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel.; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Tamir-Degabli N; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Internal Medicine E, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel., Dotan I; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Zittan E; Department of Gastroenterology and Liver Diseases, Emek Medical Center, Afula, Israel.; The Rappaport Faculty of Medicine Technion-Israel Institute of Technology, Haifa, Israel., Maharshak N; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Gastroenterology, Tel Aviv Medical Center, Tel-Aviv, Israel., Hirsch A; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Gastroenterology, Tel Aviv Medical Center, Tel-Aviv, Israel., Ben-Horin S; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel., Kopylov U; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel.
Jazyk: angličtina
Zdroj: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Jul; Vol. 58 (2), pp. 175-181. Date of Electronic Publication: 2023 May 08.
DOI: 10.1111/apt.17538
Abstrakt: Background: Curcumin and QingDai (QD, Indigo) have been shown to be effective for treating active ulcerative colitis (UC).
Aim: To evaluate the real-world experience with the Curcumin-QingDai (CurQD) herbal combination to induce remission in active UC.
Methods: A retrospec-tive multicentre adult cohort study from five tertiary academic centres (2018-2022). Active UC was defined as a Simple Clinical Colitis Activity Index (SCCAI) ≥ 3. Patients were induced by CurQD. The primary outcome was clinical remission at weeks 8-12, defined as SCCAI ≤2 and a decrease ≥3 points from baseline. Secondary outcomes were clinical response (SCCAI decrease ≥3 points), corticosteroid-free remission, faecal calprotectin (FC) response (reduction ≥50%), FC normalisation (FC ≤100 μg/g for patients with FC ≥300 μg/g at baseline), and safety. All outcomes were analysed for patients who were maintaining stable treatment.
Results: Eighty-eight patients were included; 50% were biologics/small molecules experienced, and 36.5% received ≥2 biologics/small molecules. Clinical remission was achieved in 41 (46.5%), and clinical response in 53 (60.2%). Median SCCAI decreased from 7 (IQR:5-9) to 2 (IQR:1-3); p < 0.0001. Of the 26 patients on corticosteroids at baseline, seven achieved corticosteroid-free remission. Among 43 biologics/small molecules experienced patients, clinical remission was achieved in 39.5% and clinical response in 58.1%. FC normalisation and response were achieved in 17/29 and 27/33, respectively. Median FC decreased from 1000 μg/g (IQR:392-2772) at baseline to 75 μg/g (IQR:12-136) at the end of inductions (n = 30 patients with paired samples); p < 0.0001. No overt safety signals emerged.
Conclusion: In this real-world cohort, CurQD effectively induced clinical and biomarker remission in patients with active UC, including patients who were biologics/small molecules experienced.
(© 2023 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje